Citadel Advisors
SEEL

Citadel Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Citadel Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15
Closed -$10.5K – 15483
2023
Q3 		$10.5K Buy
15
+8
+114% +$34.3K ﹤0.01% 13058
2023
Q2 		$34.3K Buy
7
+2
+40% +$6.94K ﹤0.01% 12222
2023
Q1 		$12.8K Sell
5
-15
-75% -$43.9K ﹤0.01% 13392
2022
Q4 		$52.3K Sell
20
-13
-39% -$45.3K ﹤0.01% 12074
2022
Q3 		$129K Buy
33
+24
+267% +$94.4K ﹤0.01% 10864
2022
Q2 		$24K Sell
9
-1
-10% -$2.6K ﹤0.01% 12331
2022
Q1 		$33K Sell
10
-4
-29% -$17.2K ﹤0.01% 13059
2021
Q4 		$86K Sell
14
-15
-52% -$115K ﹤0.01% 12866
2021
Q3 		$270K Sell
29
-8
-22% -$68.8K ﹤0.01% 11302
2021
Q2 		$377K Buy
37
+25
+208% +$411K ﹤0.01% 10716
2021
Q1 		$229K Buy
+12
New +$140K ﹤0.01% 11443
2015
Q2 		– Hold
0
– -$5K – 9160
2015
Q1 		– Hold
0
– – – 8326
2014
Q3 		– Hold
0
– -$2K – 8471
2014
Q2 		– Hold
0
– – – 7840
2014
Q1 		– Hold
0
– – – 7626
2013
Q4 		– Hold
0
– -$4K – 7202
2013
Q3 		– Hold
0
– – – 6606
2013
Q2 		– Hold
0
– – – 5831

Other funds holding SEEL

WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $381M AUM 21.36% 1-Year Est. Return

Citadel Advisors's SEEL Position: Q1 2024 in Review

Citadel Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2024, closing a stake of 317 shares — an estimated $56.3K sold.

Citadel Advisors first reported a position in SEEL in Q1 2018 and held it in 15 quarters. The position peaked at $592K in Q1 2021. 29 funds tracked by Wall St. Rank hold SEEL as of Q1 2024.

  • Citadel Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 317 Seelos Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $56.3K.
  • Citadel Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2018 and held it in 15 quarters.
  • Citadel Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $592K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.